The company offers an end‑to‑end biopharmaceutical platform that spans target discovery, preclinical validation, clinical development, and GMP‑grade manufacturing for antibody‑drug conjugates, large‑molecule antibodies, and small‑molecule drugs. Its OptiDC™ workflow integrates antigen selection, linker engineering, payload conjugation, and analytical characterization, and the firm provides regulatory support and contract manufacturing services to pharmaceutical and biotechnology partners.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with cancer and autoimmune disorders face limited therapeutic options because many innovative drug candidates never progress beyond early-stage research due to fragmented R&D, manufacturing, and regulatory processes. The lack of an integrated platform that can accelerate antibody‑drug conjugate (ADC), large‑molecule, and small‑molecule development creates delays and higher costs for sponsors seeking to address these unmet clinical needs.
Solution
The company operates a fully integrated biopharmaceutical pipeline that spans target discovery, preclinical validation, clinical development, GMP‑grade manufacturing, and market launch. Its proprietary OptiDC™ platform provides end‑to‑end ADC design, linker chemistry, and conjugation capabilities, while parallel large‑molecule and small‑molecule platforms support a broad therapeutic portfolio. By consolidating discovery, process development, and quality control under a single governance framework, the firm reduces hand‑off risk and shortens time‑to‑patient. The organization also offers regulatory‑science expertise and a scalable production network that can manufacture antibodies, ADCs, and chemically synthesized drugs at commercial scale. Strategic collaborations with external biotech partners allow co‑development and shared risk while leveraging the company’s platform assets. Together, these capabilities enable rapid translation of novel mechanisms into approved therapies for oncology and autoimmune indications.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to advance oncology or autoimmune drug candidates, as well as contract research organizations and academic groups that require a turnkey platform for ADC, antibody, or small‑molecule development.
Features
- OptiDC™ integrated ADC platform covering antigen selection, linker engineering, payload conjugation, and analytical characterization in a single workflow
- Dedicated large‑molecule platform for monoclonal antibodies and bispecific formats with high‑throughput cell‑line development and upstream process optimization
- Small‑molecule platform that couples medicinal chemistry, ADME screening, and GMP synthesis within a unified informatics environment
- End‑to‑end clinical development system that includes electronic trial management, biostatistics, data management, and pharmacovigilance modules
- GMP‑compliant manufacturing facilities capable of producing antibodies, ADCs, and small‑molecule APIs with validated process controls and real‑time release testing
- Integrated regulatory affairs team that prepares IND, NDA, and global registration dossiers, ensuring alignment with NMPA, FDA, EMA, and other authorities
- Flexible partnership model offering co‑development, licensing, and contract manufacturing services to external biotech and pharma sponsors